Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer

Published:2016-09-01 Issue:9 Volume:2 Page:1217
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sacher Adrian G.¹,Gandhi Leena²

Affiliation:

1. New York–Presbyterian/Columbia University Medical Center, New York

2. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts3Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 223 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial;Nature Communications;2024-08-27

2. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab;Clinical and Experimental Medicine;2024-08-06

3. Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer;Cancer Epidemiology, Biomarkers & Prevention;2024-07-02

4. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape;European Journal of Pharmaceutics and Biopharmaceutics;2024-07

5. Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion;npj Precision Oncology;2024-05-21